Role of inflammation following an acute myocardial infarction: design of INFINITY

Andreas Mitsis; Panayiotis Avraamides; John Lakoumentas; Michaela Kyriakou; Stefanos Sokratous; Georgia Karmioti; Michail Drakomathioulakis; Konstantinos C. Theodoropoulos; Athina Nasoufidou; Alexandros Evangeliou; Vassilios Vassilikos; Nikolaos Fragakis; Antonios Ziakas; Stergios Tzikas; George Kassimis

doi:10.2217/bmm-2023-0491

Role of inflammation following an acute myocardial infarction: design of INFINITY

Andreas Mitsis
, Panayiotis Avraamides
, John Lakoumentas
, Michaela Kyriakou
, Stefanos Sokratous
, Georgia Karmioti
, Michail Drakomathioulakis
, Konstantinos C. Theodoropoulos
, Athina Nasoufidou
, Alexandros Evangeliou
, Vassilios Vassilikos
, Nikolaos Fragakis
, Antonios Ziakas
, Stergios Tzikas
, George Kassimis

Research output: Contribution to journal › Article › peer-review

Abstract

After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month followup period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.

Original language	English
Pages (from-to)	971-981
Number of pages	11
Journal	Biomarkers in Medicine
Volume	17
Issue number	23
DOIs	https://doi.org/10.2217/bmm-2023-0491
Publication status	Published - 1 Dec 2023
Externally published	Yes

Keywords

acute coronary syndrome
adipokines
apelin
chemerin
cytokines
inflammation
interleukin-6
leptin
myocardial infarction
prognosis

Access to Document

10.2217/bmm-2023-0491

Cite this

Mitsis, A., Avraamides, P., Lakoumentas, J., Kyriakou, M., Sokratous, S., Karmioti, G., Drakomathioulakis, M., Theodoropoulos, K. C., Nasoufidou, A., Evangeliou, A., Vassilikos, V., Fragakis, N., Ziakas, A., Tzikas, S., & Kassimis, G. (2023). Role of inflammation following an acute myocardial infarction: design of INFINITY. Biomarkers in Medicine, 17(23), 971-981. https://doi.org/10.2217/bmm-2023-0491

@article{a2164a7f5eb94dd38c0514b8d529ded9,

title = "Role of inflammation following an acute myocardial infarction: design of INFINITY",

abstract = "After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month followup period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.",

keywords = "acute coronary syndrome, adipokines, apelin, chemerin, cytokines, inflammation, interleukin-6, leptin, myocardial infarction, prognosis",

author = "Andreas Mitsis and Panayiotis Avraamides and John Lakoumentas and Michaela Kyriakou and Stefanos Sokratous and Georgia Karmioti and Michail Drakomathioulakis and Theodoropoulos, \{Konstantinos C.\} and Athina Nasoufidou and Alexandros Evangeliou and Vassilios Vassilikos and Nikolaos Fragakis and Antonios Ziakas and Stergios Tzikas and George Kassimis",

year = "2023",

month = dec,

day = "1",

doi = "10.2217/bmm-2023-0491",

language = "English",

volume = "17",

pages = "971--981",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Taylor and Francis Ltd.",

number = "23",

}

Mitsis, A, Avraamides, P, Lakoumentas, J, Kyriakou, M, Sokratous, S, Karmioti, G, Drakomathioulakis, M, Theodoropoulos, KC, Nasoufidou, A, Evangeliou, A, Vassilikos, V, Fragakis, N, Ziakas, A, Tzikas, S & Kassimis, G 2023, 'Role of inflammation following an acute myocardial infarction: design of INFINITY', Biomarkers in Medicine, vol. 17, no. 23, pp. 971-981. https://doi.org/10.2217/bmm-2023-0491

TY - JOUR

T1 - Role of inflammation following an acute myocardial infarction

T2 - design of INFINITY

AU - Mitsis, Andreas

AU - Avraamides, Panayiotis

AU - Lakoumentas, John

AU - Kyriakou, Michaela

AU - Sokratous, Stefanos

AU - Karmioti, Georgia

AU - Drakomathioulakis, Michail

AU - Theodoropoulos, Konstantinos C.

AU - Nasoufidou, Athina

AU - Evangeliou, Alexandros

AU - Vassilikos, Vassilios

AU - Fragakis, Nikolaos

AU - Ziakas, Antonios

AU - Tzikas, Stergios

AU - Kassimis, George

PY - 2023/12/1

Y1 - 2023/12/1

N2 - After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month followup period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.

AB - After a myocardial infarction, the inflammatory response is connected to major adverse outcomes such as ischemia-reperfusion injury, adverse cardiac remodeling, infarct size and poor prognosis. INFlammatIoN amI sTudY (INFINITY) is a multicenter, prospective, observational, cohort study designed to investigate the prognostic role of the cytokines IL-6, IL-10, IL-18 and IL-17 and the adipokines leptin, apelin and chemerin in patients with acute coronary syndrome. The study will test if these inflammatory biomarkers reflect different clinical manifestations of coronary artery disease and have a prognostic role in a 6-month followup period. This study represents an opportunity to investigate further the prognostic role of a selected combination of proinflammatory and anti-inflammatory biomarkers in the prognosis and risk stratification of acute coronary syndrome patients.

KW - acute coronary syndrome

KW - adipokines

KW - apelin

KW - chemerin

KW - cytokines

KW - inflammation

KW - interleukin-6

KW - leptin

KW - myocardial infarction

KW - prognosis

UR - https://www.scopus.com/pages/publications/85183203995

U2 - 10.2217/bmm-2023-0491

DO - 10.2217/bmm-2023-0491

M3 - Article

C2 - 38235565

AN - SCOPUS:85183203995

SN - 1752-0363

VL - 17

SP - 971

EP - 981

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 23

ER -

Role of inflammation following an acute myocardial infarction: design of INFINITY

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this